ESErin Strumpf

Erin Strumpf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erin Strumpf has a total of 115 co-authors. Here are the top co-authors by number of shared publications:

  • Julie Fiset-Laniel

    Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Ave West, Montreal, QC, H3A 1A2, Canada

    4 shared publications
  • Sam Harper

    Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada

    4 shared publications
  • Arijit Nandi

    Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada

    3 shared publications
  • Mamadou Diop

    Department of Epidemiology, Biostatistics & Occupational Health, McGill University, Montreal, Quebec, Canada; Direction de santé publique du CIUSSS du Centre-Sud-de-l'Île-de-Montréal, Montreal, Quebec, Canada

    3 shared publications
  • Pierre Tousignant

    Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 1020 Pine Ave. West, Montréal, Quebec, H3A 1A2, Canada; Direction régionale de santé publique du CIUSSS du Centre-Sud-de-l'Île-de-Montréal, 1301 Sherbrooke St. East, Montréal, QC, H2L 1M3, Canada

    3 shared publications
  • Caroline King

    Department of Epidemiology, Biostatistics and Occupational Health, McGill University, 2001 McGill College, Suite 1200, Montreal, QC, H3A 1G1 Canada; l'Institute national d'excellence en santé et en services sociaux du Québec, 2021, avenue Union, 12e étage, bureau 1200, Montréal (Québec) H3A 2S9 Canada

    2 shared publications

Latest Publications

  • Paid family leave and reduced acute respiratory infections in young infants: does everyone benefit equally?

    by Katherine A Ahrens, Jennifer A Hutcheon, Erin C Strumpf, Arijit Nandi, Justin R Ortiz, Teresa Janevic

    To examine whether the effect of a paid family leave program on acute care encounters for respiratory tract infections among young infants differed by subgroups. We examined 52 943 hospitalizations and emergency department visits between October 2015 and February 2020 among infants aged ≤8 weeks in New York, which introduced paid family leave in January 2018, and four New England control states (Massachusetts, New Hampshire, Vermont, and Maine). We conducted a controlled time series analysis that compared observed counts in New York during the putative respiratory virus season (October to March) in each population subgroup to those predicted in the absence of the policy. Absolute reductions in respiratory tract infection-related acute care encounters among young infants were greater for Hispanic as compared to non-Hispanic White infants (5.60 fewer cases per 1000 infants [95% CI, -8.74 to -2.51]) and for encounters paid for by Medicaid as compared to private payer (4.22 fewer cases per 1000 [95% CI, -6.45 to -2.18]). Findings by Child Opportunity Index 2.0 quintiles showed no clear pattern. Our findings suggest the program may have larger benefits for infants from less advantaged groups.

  • Open Access

    Reporting a regular medical doctor index: A new measure of patient-physician affiliation for health administrative data

    by Caroline King, M. Ruth Lavergne, Kimberlyn McGrail, Erin C. Strumpf, on behalf of the Quebec-British Columbia Patient Enrolment Project Team

    Having a regular medical doctor is associated with better process of care and health outcomes. The goal of this study was to harness the richness in health administrative data to create a measure which accurately predicted whether patients self-identified as having a regular medical doctor. The Canadian Community Health Survey (2007–2012) was linked with health administrative data (HAD) (2002–2012) from Quebec, Canada’s second largest province. The Canadian Community Health Survey includes respondents’ answer to whether they have a regular medical doctor, but health administrative data does not. We therefore used LASSO and Random Forests to build prediction models that predict whether a patient reports having a regular medical doctor using their data only available in the HAD. Our results show that predicting patient responses to ‘do you have a regular medical doctor?’ using an average of single-year Usual Provider Continuity over 3 years results in an area under the receiver operator characteristic curve of 0.782 (0.778–0.787). This was almost a 14% improvement in predictive accuracy compared to the frequently used single-year Usual Provider Continuity (0.688 (0.683–0.694)). We have called this new measure the Reporting a Regular Medical Doctor (RRMD) index. The RRMD index is easy to implement in HAD, is an elegant solution to the difficulties associated with low-users having unstable UPC scores, and brings a patient-oriented perspective to previous efforts to capture patient-physician affiliations in HAD. We recommend that researchers seeking to measure whether patients have a regular medical doctor using HAD consider using the RRMD index.


  • Open Access

    Advanced Lung Cancer Patients’ Use of EGFR Tyrosine Kinase Inhibitors and Overall Survival: Real-World Evidence from Quebec, Canada

    by Samia Qureshi, Gino Boily, Jim Boulanger, Kossi Thomas Golo, Aude-Christine Guédon, Camille Lehuédé, Ferdaous Roussafi, Catherine Truchon, Erin Strumpf

    EGFR tyrosine kinase inhibitors (EGFR-TKIs) are breakthrough palliative treatments for advanced lung cancer patients with tumors harboring mutations in the EGFR gene. Using healthcare administrative data, three cohorts were created to describe the use of three EGFR-TKIs that are publicly funded in Quebec for specific indications (i.e., 1st-line gefitinib, 1st-line afatinib, and post-EGFR-TKI osimertinib). The main objective was to compare overall survival (OS) among patients receiving these treatments to those in previous experimental and real-world studies. The patients who received EGFR-TKIs for indications of interest between 1 April 2001, and 31 March 2019 (or 31 March 2020, for post-EGFR-TKI osimertinib) were included to estimate the Kaplan-Meier-based median OS for each cohort. An extensive literature search was conducted to include comparable studies. For the gefitinib 1st-line (n = 457), the afatinib 1st-line (n = 80), and the post-EGFR-TKI osimertinib (n = 119) cohorts, we found a median OS (in months) of 18.9 (95%CI: 16.3–21.9), 26.6 (95%CI: 13.7-NE) and 19.9 (95%CI: 17.4-NE), respectively. Out of the 20 studies that we retained from the literature review and where comparisons were feasible, 17 (85%) had similar OS results, which further confirms the value of these breakthrough therapies in real-world clinical practice.


  • Mesurer l’accès et la qualité des soins de première ligne au Québec : Réflexions issues de recherches sur la prise en charge des patients

    by Erin C. Strumpf, Laurie J. Goldsmith, Ruth Lavergne, Caroline E. King, Rita K. McCracken, Kimberlyn M. McGrail, Leora Simon

    Plus d’un million de « patients orphelins » sont toujours en attente d’un médecin de famille au Québec comme le révèle le Tableau de bord du ministère de la Santé et des Services sociaux. Ce printemps, le ministre Dubé a lancé plusieurs initiatives visant une transformation du système de santé pour assurer un accès à des soins de première ligne de qualité et dans les meilleurs délais. Ces réformes s’articulent principalement autour de l’inscription des patients auprès d’un médecin de famille. Avoir accès à une source habituelle de soins est presque universellement considéré comme étant une bonne chose. Dans ce court texte, Erin C. Strumpf, professeure à l’Université McGill et Fellow CIRANO, et ses co-auteures remettent en question cette idée. Elles montrent qu’on a trop souvent tendance à confondre les concepts et à supposer que des contacts répétés témoignent d’une véritable relation de confiance et empreinte de bienveillance qui, ultimement, amélioreront la santé du patient. Afin d’évaluer efficacement les mesures mises en place, il est essentiel d’expliciter et de clarifier les processus par lesquels les soins aux patients peuvent effectivement être améliorés et de préciser les indicateurs les plus pertinents et qui captent réellement les résultats d’intérêts. C’est ce que les auteures proposent ici. En étant honnêtes et lucides à propos de ce que nous pouvons réellement mesurer et évaluer avec les données dont nous disposons, elles sont d’avis qu’on crée une ouverture d’esprit pour des approches plus créatives en matière d’évaluation des politiques de santé.


  • Open Access

    Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration’s RWE Data Working Group

    by Wei Fang Dai, Claire de Oliveira, Scott Blommaert, Reka E. Pataky, David Tran, Zeb Aurangzeb, Cynthia Kendell, Chris Folkins, Chandy Somayaji, Jeff Dowden, et al.

    Canadian provinces routinely collect patient-level data for administrative purposes. These real-world data (RWD) can be used to generate real-world evidence (RWE) to inform clinical care and healthcare policy. The CanREValue Collaboration is developing a framework for the use of RWE in cancer drug funding decisions. A Data Working Group (WG) was established to identify data assets across Canada for generating RWE of oncology drugs. The mapping exercise was conducted using an iterative scan with informant surveys and teleconference. Data experts from ten provinces convened for a total of three teleconferences and two in-person meetings from March 2018 to September 2019. Following each meeting, surveys were developed and shared with the data experts which focused on identifying databases and data elements, as well as a feasibility assessment of conducting RWE studies using existing data elements and resources. Survey responses were compiled into an interim data report, which was used for public stakeholder consultation. The feedback from the public consultation was used to update the interim data report. We found that databases required to conduct real-world studies are often held by multiple different data custodians. Ninety-seven databases were identified across Canada. Provinces held on average 9 distinct databases (range: 8–11). An Essential RWD Table was compiled that contains data elements that are necessary, at a minimal, to conduct an RWE study. An Expanded RWD Table that contains a more comprehensive list of potentially relevant data elements was also compiled and the availabilities of these data elements were mapped. While most provinces have data on patient demographics (e.g., age, sex) and cancer-related variables (e.g., morphology, topography), the availability and linkability of data on cancer treatment, clinical characteristics (e.g., morphology and topography), and drug costs vary among provinces. Based on current resources, data availability, and access processes, data experts in most provinces noted that more than 12 months would be required to complete an RWE study. The CanREValue Collaboration’s Data WG identified key data holdings, access considerations, as well as gaps in oncology treatment-specific data. This data catalogue can be used to facilitate future oncology-specific RWE analyses across Canada.


  • Open Access

    The effects of early pregnancy loss on health outcomes and health care utilization and costs

    by Erin C. Strumpf, Nichole Austin, Ariella Lang, Shelley Derksen, James Bolton, Marni Brownell, Patricia Gregory, Dan Chateau, Maureen Heaman

    Objective: To evaluate the effects of early pregnancy loss on subsequent health care use and costs.Data Sources: Linked administrative health databases from Manitoba, Canada.Study Design: This was a population‐based cohort study. The exposure of interest was first recorded ectopic pregnancy or miscarriage (EPM). Outcomes included visits to all ambulatory care providers, family physicians (FPs), specialists, and hospitals, as well as the costs associated with these visits. We also assessed the impact of EPM on a global measure of health service utilization and the incidence and costs of psychotropic medications.Data Collection/Extraction Methods: We identified women who experienced their first recorded loss (EPM) from 2003–2012 and created a propensity score model to match these women to women who experienced a live birth, with outcome measures available through 31 December 2014. We used a difference in differences approach with multivariable negative binomial models and generalized estimating equations (GEE) to assess the impact of EPM on the aforementioned health care utilization indicators.Principal Findings: EPM was associated with a short‐term increase in visits to, and costs associated with, certain ambulatory care providers. These findings were driven in large part by increased visits/costs to FPs (rate difference [RD]: $19.92 [95% CI: $16.33, $23.51]) and obstetrician‐gynecologists (OB‐GYNs) (RD $9.41 [95% CI: $8.42, $10.40]) in the year immediately following the loss, excluding care associated with the loss itself. We also detected an increase in hospital stays and costs and a decrease in the use of psychotropic medications relative to matched controls.Conclusion: Pregnancy loss may lead to subsequent increases in certain types of health care utilization. While the absolute costs associated with post‐EPM care are relatively small, the observed patterns of service utilization are informative for providers and policy makers seeking to support women following a loss.


  • Bringing health economics knowledge to non-economists in Quebec, Canada: a case study of a multi-modal knowledge transfer approach for patient-oriented research (POR)

    by Maude Laberge, Annie Poirier, Simon Berthelot, Thomas Poder, Erin Strumpf, Hervé Tchala Vignon Zomahoun

    The medical and health services sector is increasingly looking at health economics to answer questions of resources allocation, reimbursements, and efficiency. Beneficiaries are patients and their families who carry the burden associated with their health conditions. As such, there is an increasing concern for integrating patients in research. In the context of the Canadian Strategy for Patient-Oriented Research, a team was put together in the province of Quebec to support capacity building and knowledge transfer in health economics. The team includes researchers and patients across the province. This chapter is a case study explaining the approach with the services and training tools that were developed: tutorials, a protocol review service, a mapping of resources, in-person workshops and development of tools that could support integration of the patient perspective. A discussion about the value of this project is presented.

  • Open Access

    Prevalence and clinical, social, and health care predictors of miscarriage

    by Erin Strumpf, Ariella Lang, Nichole Austin, Shelley A. Derksen, James M. Bolton, Marni D. Brownell, Dan Chateau, Patricia Gregory, Maureen I. Heaman

    Background: Pregnancy loss is common and several factors (e.g. chromosomal anomalies, parental age) are known to increase the risk of occurrence. However, much existing research focuses on recurrent loss; comparatively little is known about the predictors of a first miscarriage. Our objective was to estimate the population-level prevalence of miscarriages and to assess the contributions of clinical, social, and health care use factors as predictors of the first detected occurrence of these losses. Methods: In this population-based cohort study, we used linked administrative health data to estimate annual rates of miscarriage in the Manitoba population from 2003 to 2014, as a share of identified pregnancies. We compared the unadjusted associations between clinical, social, and health care use factors and first detected miscarriage compared with a live birth. We estimated multivariable generalized linear models to assess whether risk factors were associated with first detected miscarriage controlling for other predictors. Results: We estimated an average annual miscarriage rate of 11.3%. In our final sample (n = 79,978 women), the fully-adjusted model indicated that use of infertility drugs was associated with a 4 percentage point higher risk of miscarriage (95% CI 0.02, 0.06) and a past suicide attempt with a 3 percentage point higher risk (95% CI -0.002, 0.07). Women with high morbidity were twice as likely to experience a miscarriage compared to women with low morbidity (RD = 0.12, 95% CI 0.09, 0.15). Women on income assistance had a 3 percentage point lower risk (95% CI -0.04, -0.02). Conclusions: We estimate that 1 in 9 pregnant women in Manitoba experience and seek care for a miscarriage. After adjusting for clinical factors, past health care use and morbidity contribute important additional information about the risk of first detected miscarriage. Social factors may also be informative.